A 78-year-old female presented in 1996 with bone pain, generalized muscular weakness and immobility. She had marked hypophosphataemia and osteomalacic fractures and a clinical diagnosis of oncogernic osteomalacia was made. 1 No tumour could be identified at that time. Subsequent management, including partial parathyroidectomy, oral phosphate and 1,25-dihydroxycholecalciferol (1,25-D 3 ), produced good symptomatic improvement. In 2008, elevated levels of fibroblast growth factor (FGF)-23 were found, 18F-Deoxyglucose PET scanning became available and showed a focus of emission in the right chest ( Figure 1a ). MRI disclosed a paraspinal tumour at the level of T9 vertebral body (Figure 1b) . Further investigations showed that she had a renal Fanconi syndrome, comprising low molecular weight proteinuria, (preoperative results in Figure 2 ), glycosuria of 2.6-25 mmol/mmol creatinine (reference range <0.1) and aminoaciduria characterized by hyperglycinuria and borderline hyperlysinuria. Preoperative low molecular weight proteinuria was shown by very elevated urinary excretion of both retinol-binding protein (RBP) ( Figure 2 ) and Beta-2-microglobulin (data not shown) relative to albumin. 2 The ratio of the renal Transport Maximum of Phosphate/Glomerular Filtration rate, TmP/GFR, a measure of the threshold for urine phosphate reabsorption, was markedly reduced preoperatively, being 0.230 and 0.255 in January and March 2009, respectively; the age-and sex-adjusted reference range is 1.03 AE 0.06 mmol/l. 3 The patient underwent complete macroscopic resection of the tumour in March 2009. We measured plasma FGF-23, albuminuria and urine RBP to measure low molecular weight proteinuria, 2 TmP/GFR, glycosuria and aminoaciduria. All five measurements except aminoaciduria, were made on some 15 occasions, pre-, peri-and postoperatively and, except for urine glucose and aminoacids are shown in Figure 2 .
The resected tumour comprised primitive mesenchymal cells without evidence of malignancy. Plasma FGF-23 measured by a C-terminal assay (Immutopics Inc., San Clemente, CA, USA) fell from a preoperative level of 4500 to 314 RU/l within 24 h of tumour resection ( Figure 2a ) and was undetectable (<100) by 22 days. These results were confirmed by assay for the intact peptide (Kainos Laboratories Inc., Tokyo, Japan) (data not shown). The estimated renal threshold for plasma phosphate reabsorption, rose progressively from some 0.24 mmol/l preoperatively to 0.75 mmol/l (96 h after resection, Figure 2b) 4, 5 ). Recently, most tumours from patients with oncogenic osteomalacia have been found to express elevated levels of FGF-23 and MEPE mRNA. 5 Tumour resection in this patient with oncogenic osteomalacia due to a paraspinal tumour of mesenchymal origin, normalized plasma levels of FGF-23, the reduced threshold for phosphate reabsorption and all features of the renal Fanconi syndrome. These results are consistent with previous reports of three patients with oncogenic osteomalacia who had less complete forms of the Fanconi syndrome than our patient. [6] [7] [8] The patient reported by Evans and Azzopadi 6 showed hyperglycinuria and normoglycaemic glycosuria; the patient of Leehey et al. had a generalized hyperaminoaciduria and normoglycaemic glycosuria. Generalized aminoaciduria was also reported in the patient of Drezner and Feinglos 8 and resolved after removal of a giant cell tumour of bone. Thus, as in this patient, the pattern of aminoaciduria associated with oncogenic osteomalacia appears variable and not all patients with oncogenic ostomalacia appear to show these urine abnormalities. 9 Decreased expression of the sodium-phosphate Type 2 (NaPi-2) co-transporter in the proximal renal tubule is the putative cause of the reduced renal phosphate threshold in patients with oncogenic osteomalacia. 1 Two siblings with loss-of-function mutations of the NaPi-2 cotransporter have been reported to show a renal Fanconi syndrome and this raises the possibility that function of this transporter in oncogenic osteomalacia may be directly linked to the Fanconi syndrome.
In this patient with oncogenic osteomalacia, either plasma FGF-23, or other humoral factors highly correlated with FGF-23, caused renal Fanconi syndrome. Measurement of a urine low molecular weight protein such a retinol-binding protein should be a useful biomarker for Fanconi syndrome in patients with oncogenic osteomalacia.
